

AF \$
1646**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Jeffrey RUBIN et al.

Title: AN EPITHELIAL CELL SPECIFIC
GROWTH FACTOR,
KERATINOCYTE Growth Factor (KGF)

Appl. No.: 08/477,983

Filing Date: June 7, 1995

Examiner: Saoud

Art Unit: 1646



RECEIVED
DEC 28 2000
TECH CENTER 1600/2900

#31
J.G.J
12/28/00

AMENDMENT TRANSMITTALCommissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is Amendment A in the above-identified application.

- [] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- [] Small Entity statement is enclosed.
- [X] The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	30	- 59 = 0	x \$18.00	=	\$0.00
Independents:	6	- 3 = 3	x \$80.00	=	\$240.00
First presentation of any Multiple Dependent Claims:			+ \$0	=	0.00
			CLAIMS FEE TOTAL:	=	\$240.00

- [X] Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

12/26/2000 HVU0NG1 00000072 08477983

01 FC:120	1890.00 OP
02 FC:102	240.00 OP

146 002428917.1	710.00 OP
--------------------	-----------

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$390.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$890.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,390.00	\$0.00
<input checked="" type="checkbox"/>	Extension for response filed within the fifth month:	\$1,890.00	\$1,890.00
	EXTENSION FEE TOTAL:		\$1,890.00
	CLAIMS AND EXTENSION FEE TOTAL:		\$2,130.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
	TOTAL FEE:		\$2,130.00


- Please charge Deposit Account No. 19-0741 in the amount of \$. A duplicate copy of this transmittal is enclosed.
- A check in the total amount of \$2,840.00 is enclosed, including filing fee for Second Submission under 37 C.F.R. 1.17(r) which is \$710.00.
- The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date December 22, 2000

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5477
Facsimile: (202) 672-5399

By 
Patricia D. Granados

Patricia D. Granados
Attorney for Applicant
Registration No. 33,683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Reference No. 40399/321

Jeffrey RUBIN *et al.*
Serial No. 08/477,983
Filed: June 7, 1995

Group Art Unit: 1646
Examiner: Saoud

For: AN EPITHELIAL CELL
SPECIFIC GROWTH
FACTOR, KERATINOCYTE
Growth Factor (KGF)

Assistant Commissioner of Patents
Washington, DC 20231



RECEIVED
DEC 28 2000
TECH CENTER 1600/2900

SECOND SUBMISSION UNDER 37 CFR § 1.129

This submission is being filed pursuant to the transitional procedures set forth in Rule 129. This application was pending for more than two years as of June 8, 1995 when taking into account priority under 35 USC § 120. This application is under final rejection and no Brief on Appeal has been filed. This is the second Rule 129 submission. The fee, pursuant to Rule 1.17 (r) is attached. A Petition for Extension of Time with the requisite fee also is attached.

Please cancel all pending claims and add the following new claims:

92. An isolated keratinocyte growth factor polypeptide comprising the amino acid sequence of Figure 7 or a segment of said sequence, wherein said segment is useful in producing an antibody that

K1